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Effi cacy and Safety of Inhaled Cortico-
steroids in Patients With COPD: 
A Systematic Review and Meta-Analysis 
of Health Outcomes
ABSTRACT
PURPOSE We wanted to review systematically the effi cacy, effectiveness, and 
safety of inhaled corticosteroids with respect to health outcomes in patients with 
chronic obstructive pulmonary disease (COPD).
METHODS We searched MEDLINE, EMBASE, The Cochrane Library, and the Interna-
tional Pharmaceutical Abstracts to identify relevant articles. We limited evidence to 
double-blinded randomized controlled trials (RCTs) for effi cacy, but we also reviewed 
observational evidence for safety. Outcomes of interest were overall mortality, exac-
erbations, quality of life, functional capacity, and respiratory tract symptoms. When 
possible, we pooled data to estimate summary effects for each outcome.
RESULTS Thirteen double-blinded RCTs determined the effi cacy of an inhaled 
corticosteroid compared with placebo; 11 additional studies assessed the safety 
of inhaled corticosteroid treatment in patients with asthma or COPD. Overall, 
COPD patients treated with inhaled corticosteroids experienced signifi cantly fewer 
exacerbations than patients taking placebo (relative risk [RR] = 0.67; 95% CI, 
0.59-0.77). No signifi cant difference could be detected for overall mortality (RR 
= 0.81; 95% CI, 0.60-1.08). Evidence on quality of life, functional capacity, and 
respiratory tract symptoms is mixed. Adverse events were generally tolerable; 
pooled discontinuation rates did not differ signifi cantly between inhaled cortico-
steroid and placebo treatment groups (RR = 0.92; 95% CI, 0.74-1.14). Observa-
tional evidence, however, indicates a dose-related risk of cataract and open-angle 
glaucoma. Severe adverse events, such as osteoporotic fractures, are rare; the clini-
cal importance of the additional risk is questionable. 
CONCLUSIONS Overall, the risk-benefi t ratio appears to favor inhaled corticoste-
roid treatment in patients with moderate to severe COPD. Existing evidence does 
not indicate a treatment benefi t for patients with mild COPD.
Ann Fam Med 2006;4:253-262. DOI: 10.1370/afm.517.
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is among the lead-ing causes of morbidity and mortality worldwide.1 In 2000 COPD accounted for approximately 20.7 million outpatient visits, 3.4 mil-
lion emergency department visits, 6.3 million hospitalizations, and 116,513 
deaths in the United States.2 The World Health Organization estimates 
that by the year 2020, COPD will be the third-leading cause of death and 
the fi fth-leading cause of disability worldwide.1
COPD is characterized by a progressive, irreversible limitation of 
airfl ow associated with an abnormal infl ammatory response to noxious par-
ticles or gases. It is caused primarily by smoking.3,4
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INHALED CORTICOSTEROIDS AND COPD
The benefi cial effect of inhaled corticosteroid 
treatment for COPD remains controversial,3,5 in part 
because only smoking cessation is reliably shown to 
slow the rate of decline in lung function.4 Although 
the Food and Drug Administration (FDA) has not 
approved inhaled corticosteroids as monotherapy for 
the treatment of COPD, they are frequently prescribed 
to reduce or alleviate symptoms, increase exercise 
capacity, reduce the number and severity of exacerba-
tions, and improve health status. The Global Initiative 
for Chronic Obstructive Lung Disease recommends 
inhaled corticosteroid treatment for patients with 
COPD who have a documented spirometric response 
to inhaled corticosteroids and for patients with moder-
ate to severe COPD (forced expiratory volume in 1 
second [FEV1] <50% predicted) who have repeated 
exacerbations that require treatment with antibiotics or 
oral corticosteroids.6 Inhaled corticosteroid treatment 
is, however, associated with rare but potentially serious 
adverse events, such as osteoporosis, glaucoma, and cat-
aract, that are diffi cult to identify in effi cacy studies.7 
Six inhaled corticosteroids are available in the 
United States: beclomethasone dipropionate (beclo-
methasone), budesonide, fl unisolide, fl uticasone propio-
nate (fl uticasone), mometasone furoate (mometasone) 
and triamcinolone acetonide (triamcinolone). Table 1 
summarizes their generic names, trade names, manu-
facturers, dosage form with corresponding devices, 
strengths, and labeled uses. 
Most published studies and systematic reviews8-10 






Device Strength Labeled Uses
Beclomethasone 
dipropionate
QVAR Ivax / 3M MDI (HFA) 40 µg/puff
80 µg /puff
Asthma (aged ≥5 y)
Maintenance
Systemic corticosteroid reduction
Vanceril* Schering-Plough MDI† 42 µg /puff
84 µg /puff










AstraZeneca Inhalation suspension 500 µg
1,000 µg
2,000 µg
Asthma (aged 1-8 y)
Flunisolide AeroBid
AeroBid-M
Forest / 3M MDI†
MDI-menthol†
250 µg/puff Asthma (aged ≥6 y)
Maintenance
Systemic corticosteroid reduction
Bronalide‡ Boehringer Ingelheim 
(Canada)





Flovent GlaxoSmith-Kline MDI† 44 µg/puff
110 µg/puff
220 µg/puff
































Azmacort Aventis MDI† – with spacer 
mouthpiece
100 µg/dose Asthma (aged ≥6 y)
Maintenance
Systemic corticosteroid reduction 
MDI = metered dose inhaler; HFA = hydrofl uoroalkane propellant; DPI = dry powder inhaler.
* Currently not available from the manufacturer.
† Contains chlorofl uorocarbons.
‡ Not available in the United States.
§ Discontinued by manufacturer; supplies should be depleted by end of fi rst quarter 2005, at which time Flovent HFA will replace Flovent.
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have evaluated the effect of inhaled corticosteroid 
treatment on FEV1 decline. The rate of FEV1 descent, 
however, is an imperfect surrogate outcome for clinically 
important health outcomes, such as health-related quality 
of life, functional capacity, and exacerbations.11 Only one 
meta-analysis focused primarily on health outcomes12; 
none of these systematic reviews took observational 
evidence for adverse events into consideration. Limit-
ing adverse events assessment to randomized controlled 
trials (RCTs) risks missing rare but potentially severe 
adverse events, such as osteoporotic fractures, glaucoma, 
or cataract, which RCTs cannot reliably assess because of 
limitations of sample sizes and study durations. 
The objective of this review is to determine the 
risk-benefi t ratio of inhaled corticosteroid treatment 
for COPD by systematically reviewing the evidence 
on the effi cacy, effectiveness, and safety of inhaled 
corticosteroid treatment in patients with COPD with 
respect to health outcomes. Contrary to previous 
systematic reviews, because our review incorporates 
observational evidence for adverse events, we provide 
the fi rst comprehensive assessment of the risk-benefi t 
ratio of inhaled corticosteroid treatment for COPD.
METHODS
This study is part of a larger systematic review of the 
comparative effectiveness and tolerability of inhaled 
corticosteroids in patients with asthma or COPD 
conducted for the Oregon Drug Effectiveness Review 
Project (DERP).13 We limited outcomes of interest a 
priori to health outcomes to assure clinical applicabil-
ity of results.
We searched MEDLINE, EMBASE, The Cochrane 
Library, and the International Pharmaceutical Abstracts 
to identify relevant articles. We used either medical 
subject headings (MeSH or MH) as search terms when 
available or key words when appropriate. We com-
bined terms for the selected indication (COPD) and 
adverse events with 6 specifi c inhaled corticosteroids 
(beclomethasone, budesonide, fl unisolide, fl uticasone, 
mometasone, and triamcinolone). We limited the elec-
tronic searches to “human” and “English language”; we 
searched sources from 1970 to 2005 (April) to capture 
literature relevant to the scope of our topic.
Two persons independently reviewed abstracts; 
if both reviewers agreed that the trial did not meet 
eligibility criteria, it was excluded. We reviewed the 
full text of all eligible articles. Double-blind RCTs of 
at least 6 months’ duration and an outpatient study 
population were eligible for inclusion. Preestablished 
exclusion criteria concerned study design or duration, 
patient population, interventions, and outcomes. We 
excluded open-label studies from the effi cacy analy-
sis because empirical evidence indicates that lack of 
blinding frequently leads to measurement bias and an 
overestimation of effect sizes.14 For adverse events we 
included both experimental and observational studies. 
For observational studies we included those with large 
sample sizes (>100 patients) that lasted at least 1 year 
and reported an included outcome. For adverse events 
we also included evidence from mixed populations 
with asthma and/or COPD. 
We assessed the internal validity (quality) of trials 
based on predefi ned criteria from the US Preventive 
Services Task Force (ratings: good-fair-poor)15 and 
the National Health Service Centre for Reviews and 
Dissemination.16 External validity (generalizability) 
was assessed but did not infl uence quality ratings. We 
rated trials with a fatal fl aw in one or more categories 
as poor quality and excluded them from the analysis; 
we rated trials that met all criteria as good quality. The 
majority of trials received a quality rating of fair. We 
accepted the defi nitions of exacerbation as reported 
in each study because we did not have access to indi-
vidual patient data. Although defi nitions of exacerba-
tion varied across studies, most defi ned it as an episode 
requiring oral or parenteral corticosteroids, antibiot-
ics, emergency department visits, or hospitalizations 
because of increased respiratory tract symptoms. 
When possible, we pooled data to obtain summary 
effect estimates for a given outcome, using relative 
risks to measure effect sizes. We used fi xed-effects 
models for all meta-analysis because the observed 
heterogeneity was low (<20%, assessed using the I2 
statistic). We assessed publication bias using funnel 
plots and Kendall’s tests, although the validity of these 
methods is limited given the small number of compo-
nent studies. All analyses were conducted using Stats-
Direct 2.3.8 (StatsDirect Ltd, Sale, Cheshire, UK).
RESULTS
Overall we identifi ed 880 citations. Figure 1 illustrates 
the disposition of citations and articles. Thirteen dou-
ble-blinded RCTs determined the effi cacy of an inhaled 
corticosteroid compared with placebo in patients 
with COPD. We excluded 1 study for quality reasons 
because of a high rate of postrandomization exclusions.17 
We included 11 additional studies conducted in adult 
patients with COPD or asthma to assess the risk of 
adverse events of long-term inhaled corticosteroid use. 
Tables 2 and 3 describe included studies.18-40 In effi -
cacy studies, patients were generally smokers or former 
smokers with a clinical diagnosis of COPD. Only the 
Copenhagen City Lung Study enrolled smokers identi-
fi ed as having mild COPD during a random population 
survey and subsequent respiratory system screening.23 
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Severity of COPD varied from mild to severe across 
studies; inclusion criteria tended to exclude patients with 
asthma or good bronchodilator responsiveness. Patients 
with a history of asthma, allergic disease, or sudden onset 
of breathlessness were excluded from all studies. Further, 
FEV1 reversibility after bronchodilator use was frequently 
assessed before enrollment; cutoff criteria were between 
10% and 15%. Nine trials (69%) were funded by phar-
maceutical companies and 3 (23%) were supported pri-
marily by governmental agencies or independent funds; 
1 study (7%) did not report funding source.
Exacerbations 
Two studies did not provide suffi cient data on exac-
erbation rates and could not be included in the meta-
analyses.20,21 Overall, pooled results of 4,300 patients 
from the 10 remaining trials showed a 33% reduction 
(95% CI, 23%-41%; RR = 0.67; 95% CI, 0.59-0.77) 
in COPD exacerbation rates over a mean follow-up 
period of 20.8 months (Figure 2A). Sensitivity analy-
sis showed that this treatment effect derives largely 
from studies in populations suffering from moderate 
to severe COPD (respectively, FEV1 ≥50% to <80% 
predicted and FEV1 <50% predicted according to 
American Thoracic Association criteria).41 Limiting the 
analysis to the 7 trials with populations with moder-
ate to severe COPD (ie, excluding populations with 
mild COPD) produces an estimated benefi t of inhaled 
corticosteroid treatment almost identical to the results 
of the overall meta-analysis (RR = 0.66; 95% CI, 0.57-
0.75) (Figure 2B). The number needed to treat (NNT) 
in this population is 12 (95% CI, 9-18); ie, 12 patients 
with moderate to severe COPD need to be treated 
with an inhaled corticosteroid for 17.7 months to avoid 
1 exacerbation. For the population with mild COPD 
(FEV1 ≥80% predicted), we pooled results of 3 small 
studies (n = 191); no benefi t of inhaled corticosteroid 
treatment emerged (RR = 0.92; 95% CI, 0.55-1.53). 
As noted, the sample size of this analysis is small, and 
point estimates of both subgroup analyses are within 
each other’s confi dence intervals. Inferences about dif-
ferences of treatment effects must be made cautiously.
In sensitivity analyses we compared pooled 
results of studies of newer inhaled corticosteroids 
(ie, fl uticasone) that have a large degree of 
fi rst-pass metabolism42,43 with those of older 
inhaled corticosteroids (ie, beclomethasone, 
budesonide, fl unisolide, and triamcinolone). 
Relative benefi ts of both groups were almost 
identical (newer inhaled corticosteroids: RR 
= 0.69 [0.59-0.80]; older inhaled corticoste-
roids: RR = 0.65 [95% CI, 0.53-0.79]).
Mortality
The pooled relative risks (RR = 0.81; 95% CI, 
0.60-1.08) for 4,370 patients resulted in no sig-
nifi cant difference in all-cause mortality (Fig-
ure 3A). Overall, 2.9% of patients on placebo 
and 2.5% of patients on inhaled corticoste-
roids died (P = .27) during the mean follow-up 
period of 22.3 months. Limiting the analysis to 
studies of moderate to severe COPD (Figure 
3B) yielded almost identical results (RR = 0.84; 
95% CI, 0.61-1.15). No differences in mortality 
were apparent between groups taking newer 
and older inhaled corticosteroids.
Functional Capacity and Quality of Life
In the few studies that assessed functional 
capacity or quality of life, outcome measures 
were too heterogeneous to pool results in a 
meta-analysis; therefore, we analyzed fi ndings 
qualitatively.
Five studies examined functional capacity 
and quality of life in patients with moder-
ate to severe COPD.18,19,22,26,27 Two trials 
Figure 1. Results of literature search.
Citations identifi ed through systematic 
literature search: n = 880
Titles and abstracts excluded: 
n = 792
Full-text articles retrieved for 
more detailed evaluation: n = 88
Studies included in systematic review: 
n = 23
RCTs on effi cacy: n = 12
Budesonide vs placebo: 6
Flunisolide vs placebo: 0
Fluticasone vs placebo: 5
Triamcinolone vs placebo: 1





RCTs excluded: n = 13
Wrong outcome measure: 2
Population not included: 4
Wrong study design: 6
Poor internal validity: 1
Background: 
n = 52
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Table 2. Summary of Included Randomized Controlled Trials on Effi cacy of Inhaled Corticosteroids in COPD
Author, Year
Mean Age 






Bourbeau et al,18 1998 66 79 6 mo 1,600 µg/d, DPI 36.5 Fair
Calverley  et al,19 2003 64 513 1 y 800 µg/d, DPI 36 Fair
Pauwels et al,20 1999 (EUROSCOP) 52 1,277 3 y 800 µg/d, DPI 77 Fair
Renkema et al,21 1996 55 40 2 y 1,600 µg/d, MDI 64 Fair
Szafranski et al,22 2003 64 403 1 y 800 µg/d, MDI 36 Fair
Vestbo et al,23 1999 59 290 3 y 1,200 µg/d, DPI 86 Fair
Fluticasone vs placebo
Albers et al,24 2004 50 85 2 y 500 µg/d, MDI 90 Good
Burge et al,25 2000 (ISOLDE) 64 751 3 y 1,000 µg/d, MDI 50 Fair
Calverley et al,26 2003 63 735 1 y 1,000 µg/d, DPI 45 Good
Paggiaro et al,27 1998 63 281 6 mo 1,000 µg/d, MDI 57 Good
van Grunsven et al,28 2003 47 48 2 y 500 µg/d, DPI 96 Fair
Triamcinolone vs placebo
Lung Health Study29 56 1,116 3 y, 4 mo 1,200 µg/d, MDI 64 Fair
COPD = chronic obstructive pulmonary disease; DPI = dry powder inhaler; MDI = metered dose inhaler.
Table 3. Summary of Included Studies on Adverse Events of Inhaled Corticosteroids in COPD
Author, Year N Design Population Results
Quality 
Rating
Bone density and osteoporotic fractures
Jones et al,30 2004 NA Systematic review Asthma and COPD No difference in BMD and osteoporotic 
fractures between ICS and placebo
Fair
Hubbard et al,31 2002 16,341 Case-control Asthma and COPD Nonspecifi c ICS use associated with 
a small increase in the risk of hip 
fracture
Good
Israel et al,32 2001 109 Prospective cohort Women (aged 18-45 y) Triamcinolone associated with dose-
related decline in BMD (total hip and 
trochanter) of 0.00044 g/cm2 per 
puff/year 
Fair
Johnell et al,33 2002 1,277 RCT COPD No difference in bone density between 
BUD and placebo over 3 y; no differ-
ence in bone density or vertebral frac-
tures in subgroup of 912 smokers
Fair
Lee & Weiss,34 2004 8,525 Nested case-control COPD Nonspecifi c ICS use associated with 
increased risk of fractures at high doses
Good
Posterior subcapsular cataracts
Cumming et al,35 1997 3,654 Cross-sectional Adults; asthma and 
COPD; aged 49-97 y
Increased risk of nuclear and PSC 
among ICS users
N/A
Garbe et al,36 1998 25,545 Case-control RAMQ; asthma and 
COPD; aged ≥70 y
Increased risk of cataract extraction 
for ICS users only at high dose and 
duration
Good
Jick et al,37 2001 201,816 
(3,581)
Cohort + case-control GPRD; asthma and 
COPD; aged 3-90 y
Dose-, duration-, and age-related 
increased risk of cataracts among ICS 
users; no increase in risk for age <40
Good
Smeeth et al,38 2003 30,958 Case-control GPRD; asthma and 
COPD; aged ≥40 y
Dose- and duration-related increased 
risk of cataracts among ICS users
Good
Ocular hypertension and open-angle glaucoma
Garbe et al,39 1997 48,118 Case-control RAMQ aged ≥66 y ≥3 mo high-dose ICS associated with 
increased risk of open-angle glau-
coma and ocular hypertension 
Fair
Mitchell et al,40 1999 3,654 Cross-sectional Adults; asthma and 
COPD; aged 49-97 y
Dose-related increased risk of elevated 
IOP and open-angle glaucoma for ICS 
users with glaucoma family history
N/A
COPD = chronic obstructive pulmonary disease; NA = not applicable; BDP = beclomethasone dipropionate; BMD – bone mineral density; ICS = inhaled corticosteroid; 
RCT = randomized controlled trial; BUD = budesonide; PSC = posterior subcapsular cataracts; RAMQ = regi de l’assurance maladie du Quebec database; GPRD = gen-
eral practice research database; IOP = intraocular pressure.
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administered a 6-minute walking test after 6 months 
of inhaled corticosteroid treatment. In one, 6-minute 
walking distance was signifi cantly greater for patients 
on fl uticasone 1,000 mg/d than for patients on placebo 
(+27 m vs +9 m; P = .032).27 A smaller Canadian study 
did not detect any signifi cant difference in walking dis-
tances for patients when comparing budesonide 1,600 
mg/d with placebo (-15 m vs +13 m; P = NR).18 This 
trial also reported no signifi cant differences in scores 
on the Chronic Respiratory Disease Questionnaire. 
Three studies of patients with 
severe COPD reported greater 
improvements in St. George’s 
Respiratory Questionnaire for 
patients on budesonide 800 mg/d 
or fl uticasone 1,000 µg/d than for 
patients on placebo19,22,26; how-
ever, the clinical importance of 
the reported differences (range: 
-0.8 to -3.0) is uncertain.
Two Dutch studies originat-
ing from the DIMCA (Detection, 
Intervention, and Monitoring of 
COPD and Asthma) program, 
which recruited patients with 
mild COPD through population 
screening, did not fi nd any dif-
ferences in functional capacity 
for patients on fl uticasone 500 
mg/d and those on placebo after 
2 years of treatment.24,28
Respiratory Symptoms
Most studies assessed respiratory 
system symptom scores, but the 
reported data were mixed and 
insuffi cient for meta-analysis. 
Four studies reported no signifi -
cant differences in respiratory 
system symptoms when compar-
ing inhaled corticosteroid with 
placebo.18,23,26,28 Three studies 
detected no overall differences in 
respiratory systems symptoms but 
did detect signifi cant improve-
ments in subscales, such as daily 
cough scores, sputum volume,27 
night time awakenings,19 and dys-
pnea.29 In comparisons with pla-
cebo, 1 trial reported signifi cantly 
lower symptom scores in patients 
during 2 years’ treatment with 
budesonide 1,600 mg/d21 and 
another during 3 years’ treatment 
with fl uticasone 1,000mg/d.25
Adverse Events
Effi cacy trials commonly reported 
rhinitis, oral candidiasis, sore 
Figure 2. Relative risk meta-analysis of effects of inhaled 
corticosteroids on exacerbations.
A. ICS vs placebo in mild to severe COPD (fi xed effects)
B. ICS vs placebo in moderate to severe COPD (fi xed effects)
Albers et al24 0.46 (0.14, 1.52)
Bourbou et al18 0.41 (0.10, 1.72)
Burge et al25 (ISOLDE) 0.75 (0.50, 1.12)
Calverley et al26 0.77 (0.46, 1.29)
Calverley et al19 0.66 (0.38, 1.16)
Lung Health Study et al29 0.66 (0.50, 0.88)
Paggiaro et al21 0.67 (0.56, 0.79)
Szafranski et al22 0.51 (0.34, 0.75)
van Grunsven et al26 (DIMCA) 1.50 (0.51, 4.49)
Vestbo et al23 0.96 (0.50, 1.84)
Combined (fi xed) 0.67 (0.59, 0.77)
 0.01 0.1 0.2 0.5 1 2 5
Relative Risk (95% Confi dence Interval)
Favors ICS Favors Placebo
Bourbou et al18 0.41 (0.10, 1.72)
Burge et al25 (ISOLDE) 0.75 (0.50, 1.12)
Calverley et al26 0.76 (0.46, 1.28)
Calverley et al19 0.66 (0.38, 1.16)
Lung Health Study et al29 0.66 (0.50, 0.88)
Paggiaro et al21 0.67 (0.56, 0.79)
Szafranski et al22 0.51 (0.34, 0.75)
Combined (fi xed) 0.67 (0.59, 0.77)
 0.01 0.1 0.2 0.5 1 2
Relative Risk (95% Confi dence Interval)
Favors ICS Favors Placebo
ICS = inhaled corticosteroid; COPD = chronic obstructive pulmonary disease.
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throat, bruising, hoarseness, 
headache, cough, bronchitis, and 
upper respiratory infection. In 
most studies, incidence was below 
10%. Pooled discontinuation rates 
because of adverse events did 
not differ signifi cantly between 
inhaled corticosteroids and pla-
cebo (RR = 0.92; 95% CI, 0.74-
1.14). Most studies combined 
patient-reported adverse events 
with a regular clinical examination 
by an investigator. Short study 
durations and small sample sizes 
limited the validity of adverse 
events assessment in many trials. 
Many studies excluded eligible 
participants that did not toler-
ate treatment during the run-in 
period, limiting the generalizabil-
ity of adverse events assessment. 
To take the limitations of 
RCTs into consideration and to 
assess rare but potentially serious 
adverse events, we also reviewed 
observational studies (Table 3). 
Specifi cally, we were interested in 
osteoporosis, posterior subcapsu-
lar cataracts, ocular hypertension, 
and open-angle glaucoma. 
Bone Density and Osteoporotic 
Fractures
Overall, the evidence of an 
association between inhaled cor-
ticosteroid products and osteo-
porosis is mixed. A meta-analysis 
of randomized trials found no 
evidence of increased risk of loss 
of bone mineral density (BMD) 
or fractures,30 which is consistent 
with fi ndings from an RCT not 
included in that meta-analysis.20,33
The strongest observational 
evidence comes from 2 case-con-
trol studies that measured frac-
tures31,34; both reported a slight 
increase in the risk of fracture 
for inhaled corticosteroid-treated 
patients. In 1 study, only current 
high-dose users (≥700 µg/d) had 
an increased risk of nonvertebral 
fractures (OR = 1.68; 95% CI, 
1.10-2.57).34 In the other, the 
Figure 3. Relative risk meta-analysis of effects of inhaled 
corticosteroids: all-cause mortality.
A. ICS vs placebo in mild to severe COPD (fi xed effects)
B. ICS vs placebo in moderate to severe COPD (fi xed effects)
Albers et al24 1.0000 (0.0132, 76.0035)
Bourbou et al18 1.0000 (0.0129, 77.6572)
Burge et al25 (ISOLDE) 0.8865 (0.5648, 1.3906)
Calverley et al26 1.1907 (0.3905, 3.6345)
Calverley et al19 0.4826 (0.1740, 1.3351)
Lung Health Study et al29 0.7866 (0.4085, 1.5138)
Paggiaro et al21 0.9789 (0.0001, 7522.5070)
Pauwels et al20 (EUROSCOP) 0.8114 (0.3320, 1.9815)
Renkema et al21 1.0000 (0.0118, 84.8803)
Szafranski et al22 0.5752 (0.2050, 1.6064)
van Grunsven et al26 (DIMCA) 1.0002 (0.0095, 106.0307)
Vestbo et al23 1.0000 (0.2786, 3.5896)






















Relative Risk (95% Confi dence Interval)
Favors ICS Favors Placebo
ICS = inhaled corticosteroid; COPD = chronic obstructive pulmonary disease.
Bourbou et al18 1.0000 (0.0129, 77.6572)
Burge et al25 (ISOLDE) 0.8865 (0.5648, 1.3906)
Calverley et al26 1.1907 (0.3905, 3.6345)
Calverley et al19 0.9317 (0.0120, 72.1699)
Lung Health Study et al29 0.7866 (0.4085, 1.5138)
Paggiaro et al21 0.9789 (0.0001, 7522.5070)
Pauwels et al20 (EUROSCOP) 0.8114 (0.3320, 1.9815)
Renkema et al21 1.0000 (0.0118, 84.8803)
Szafranski et al22 0.5752 (0.2050, 1.6064)
Combined (fi xed) 0.8064 (0.6000, 1.0838)






















Relative Risk (95% Confi dence Interval)
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risk of hip fracture was signifi cantly higher in patients 
using an inhaled corticosteroid (OR = 1.19; 95% CI, 
1.10-1.28). Additionally, evidence of an inhaled cor-
ticosteroid-associated reduction in BMD comes from 
a prospective cohort study in 109 premenopausal 
women32: an estimated bone loss of 0.00044 g/cm2 per 
puff per year of treatment. We view BMD as an inter-
mediate outcome measure of osteoporosis; although a 
causal relationship exists between loss of BMD and risk 
of fractures from osteoporosis, the clinical importance 
of modest changes in BMD is often questionable. 
Cataracts
The association between systemic corticosteroids and 
cataracts, especially at high doses administered for 
extended periods, is well documented in both children44 
and adults.45 Systemic corticosteroid-induced cataracts 
typically are located on the posterior side of the lens 
and are referred to as posterior subcapsular cataracts. 
Four observational studies evaluated the risk of 
adult patients developing cataracts, comparing nonspe-
cifi c inhaled corticosteroid use with no inhaled corti-
costeroid use.35-38 
A British case-control study of 15,479 patients with 
cataracts detected a modest but signifi cant increase 
in risk for the overall use of inhaled corticosteroids 
(adjusted OR = 1.10; 95% CI, 1.00-1.20).38 A sub-
group analysis of COPD patients, however, showed no 
signifi cant increase in risk (adjusted OR = 1.03; 95% 
CI, 0.94-1.13). These results suggest a cumulative risk 
of inhaled corticosteroid use for the development of 
cataracts, because patients with asthma are generally 
exposed to inhaled corticosteroids for longer periods 
of their lives than are patients with COPD. 
These fi ndings are consistent with other observa-
tional evidence in patients with asthma or COPD. A 
retrospective cohort study with a nested case-control 
study,37 a case-control study,36 and a cross-sectional 
study35 reported increased dose- and duration-dependent 
risks of inhaled corticosteroids use for posterior cataract. 
These studies do not report on COPD patients alone. 
Ocular Hypertension and Open-Angle Glaucoma 
In 1 case-control study of 48,118 Canadians aged 66 
years and older39 and 1 cross-sectional population-based 
eye study of 3,654 Australians aged 49 to 97 years,40 
the risk of increased intraocular pressure or open-angle 
glaucoma was compared in patients using inhaled cor-
ticosteroids and patients not using inhaled corticoste-
roids. Both studies adjusted for age, sex, oral steroid use, 
history of diabetes, and history of hypertension but did 
not stratify by COPD patients. Both reported a dose-
related increase in the risk of open-angle glaucoma for 
inhaled corticosteroid-treated patients compared with 
patients who had not used an inhaled corticosteroid.39,40 
The case-control study observed this relationship only 
among current users of high doses of inhaled corti-
costeroids prescribed regularly for 3 or more months 
(adjusted OR = 1.44; 95% CI, 1.01-2.06)39; patients on 
low to medium doses did not have an increased risk 
(adjusted OR = 0.95; 95% CI, 0.77-1.19). In the cross-
sectional study the association between ever using 
inhaled corticosteroids and elevated intraocular pressure 
or glaucoma occurred only in patients with a family his-
tory of glaucoma (OR = 2.8; 95% CI, 1.2-6.8).40
DISCUSSION
Our meta-analysis suggests that COPD patients 
treated with inhaled corticosteroids experience sig-
nifi cantly fewer exacerbations than patients on pla-
cebo. The relative risk reduction is 33%; the NNT 
to prevent 1 exacerbation during 20.8 months is 12. 
This treatment effect is apparently stronger in patients 
with moderate to severe COPD. Pooled estimates for 
patients with mild COPD did not suggest a reduction 
of exacerbations. Sample sizes are too small, however, 
for clear inferences about the effi cacy of inhaled corti-
costeroid treatment in patients with mild COPD. 
We could not detect a signifi cant benefi t of inhaled 
corticosteroid treatment with respect to overall mortal-
ity, which in part may be attributable to short study 
durations (maximum 3 years) relative to the long natural 
course of disease and to the lack of power to detect 
such an outcome. We chose overall mortality as an 
outcome measure rather than COPD mortality, as it 
does not depend on a subjective judgment by outcome 
assessors and is therefore less prone to bias. The body 
of evidence concerning quality of life and functional 
capacity is mixed and yields no basis for clear conclu-
sions. Empirical evidence suggests, however, that patient 
quality of life is related to the frequency of COPD 
exacerbation.46,47 Thus, fewer exacerbations resulting 
from inhaled corticosteroid treatment can provide indi-
rect evidence for improved quality of life. In addition, 
inhaled corticosteroid treatment will spare some patients 
from dealing with systemic corticosteroids.
Effi cacy data indicate that adverse events are usu-
ally mild and do not lead to signifi cantly higher discon-
tinuation rates for inhaled corticosteroid-treated than 
for placebo-treated patients. Osteoporotic fractures are 
rare; the clinical importance of the additional risk is 
questionable. Evidence from large observational stud-
ies consistently indicates a modest risk of cataracts and 
open-angle glaucoma; it is attributable largely to high 
dosage and long duration of inhaled corticosteroid use. 
Our fi ndings are partly consistent with earlier 
meta-analyses that assessed exacerbation rates.9,12 Van 
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Grunsven et al9 reported no signifi cant differences 
in exacerbation rates between the group on inhaled 
corticosteroids and the group on placebo. Results of a 
meta-analysis by Sin et al12 are consistent with our fi nd-
ings.Point estimates from our analyses, however, are 
more precise because of the greater number of com-
ponent studies. Furthermore, neither of the 2 previous 
reviews included observational evidence for adverse 
events to assess the risk-benefi t ratio of inhaled corti-
costeroid treatment. Results of long-term observational 
studies with respect to exacerbations and mortality are 
mixed.48-53 The COPE study, a double-blind discon-
tinuation study of fl uticasone (1,000 μg/d), reported 
that patients who discontinued inhaled corticosteroid 
therapy had a signifi cantly higher recurrence risk of 
exacerbations than patients who remained on fl utica-
sone treatment.49
We note several limitations in this literature and our 
work. Durations of effi cacy studies are usually too short 
and sample sizes too small to assess reliably the effects 
on rare long-term outcomes (eg, mortality) and on rare 
but severe adverse events. Observational studies posed 
methodological concerns that precluded meta-analysis.
Because we did not have access to individual 
patient data, we assumed that defi nitions of exacerba-
tions did not differ substantially across trials. Although 
this assumption could lead to some imprecision with 
respect to effi cacy, it might also increase external 
validity because it synthesizes various defi nitions of 
exacerbation used in clinical practice. Moreover, we 
reviewed inhaled corticosteroids as a class, not tak-
ing differences in potency, delivery device, systemic 
exposure, and dosing into consideration. No treatment 
regimen appeared to be underdosed; however, because 
we could not conduct quantitative analyses on adverse 
events, we were unable to assess whether inhaled 
corticosteroids with low systemic absorption lead to 
fewer adverse events than inhaled corticosteroids with 
high systemic absorption. Our pooled effi cacy results 
might underestimate treatment effects for patients with 
severe COPD who usually receive high-dose treat-
ments. Differential loss to follow-up might also dilute 
treatment effects. Placebo groups consistently had a 
higher dropout rate than inhaled corticosteroid groups. 
The frequency of exacerbations and mortality might 
therefore be underestimated for placebo treatment.
None of the included studies can be viewed as an 
effectiveness trial with a high degree of generaliz-
ability. The patient populations often were highly 
selected and included exclusively current or former 
smokers. Patients with FEV1 reversibility of more than 
10% to 15% were typically excluded. These factors 
further limit the generalizability of results for non-
smoking patients with asthma who have chronic air-
ways obstruction. Even so, good evidence exists from 
multiple trials that inhaled corticosteroid treatment is 
effi cacious in patients with asthmatic features.13 
Finally, we could not include unpublished studies; 
their absence may lead to an overestimation of treat-
ment effects. 
Additional large studies are needed that have the 
necessary power to address such health outcomes as 
mortality and quality of life. Results of the ongoing 
TORCH (Towards a Revolution in COPD Health) 
survival study may provide answers to some remaining 
questions.54 This 3-year, multicenter trial is random-
izing approximately 6,200 patients with moderate to 
severe COPD to placebo, fl uticasone, fl uticasone/sal-
meterol, or salmeterol; it will end in 2006. 
To read or post commentaries in response to this article, see it 
online at http://www.annfammed.org/cgi/content/full/4/3/253. 
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